community acquired pneumonia (cap), uncomplicated · pdf fileclinical pathway page 1 of 15...

15
CLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment a For all patients: · If an atypical pathogen is suspected (Chlamydophilia pneumoniae, Bordatella pertussis, or Mycoplasma pneumoniae) include azithromycin g · If CA-MRSA is suspected, substitute clindamycin or vancomycin. · If suspected or confirmed influenza, consider antiviral (refer to CDC website for current recommendations). Inclusion criteria: Previously healthy pts 90 days through 21 years of age with signs, symptoms, or suspected diagnosis of uncomplicated pneumonia acquired by exposure to organisms in the community. Exclusion criteria: Pts < 90 days of age (refer to infant fever guidelines) Pts with complicated pneumonia (refer to complicated pneumonia guideline) Immune-compromised host Medically complicated pts Pts in need of critical care Systemic illness concerning for sepsis, hospital acquired pneumonia, or illness neccessitating ICU admit Failed outpatient PO therapy, decreased GI absorption, or not tolerating PO? Treat with IV antibiotics b (follow algorithm) Treat with oral antibiotics b (follow algorithm) Yes No Less than 2 doses of HiB vaccine? c Less than 2 doses of HiB vaccine? c Treat with IV: · ampicillin/ sulbactam or · ceftriaxone or · cefotaxime Treat with IV ampicillin Treat with oral amoxicillin/ clavulanate d or certain oral cephalosporins e Treat with oral amoxicillin f a: Patients with complicated pneumonia (i.e. empyema, large effusion), immunocompromised patients, patients in need of immediate critical care, and those patients with concern for sepsis do NOT fall under this treatment algorithm. Failure of outpatient oral therapy is defined as fever greater than or equal to (≥)38.0°C lasting greater than or equal to (≥) 48 hours 1, and may be due to inadequate choice or dosing of antibiotic, poor compliance, natural history of disease, or resistant organism. b: This is intended for uncomplicated cases only. See Table 3 for dosing recommendations, cost comparisons, and other implications of therapy. c: Assess whether the patient has had 2 or more doses of the H. influenzae type B (HiB) vaccine and consider the risk for invasive H. influenzae B disease based on the vaccine coverage in your community (herd protection). d: Amoxicillin component should be dosed at 90mg/kg/day divided TID if concerned for S. pneumoniae or other isolates with higher MICs (including H. influenzae and S. aureus). If using 90mg/kg/day divided TID dosing, use high dose formulation (Amox/Clav ES Suspension 600mg/5mL 42.9mg/5mL or Amox/Clav 875mg-125mg tablets). e: Oral cephalosporin formulations are considered pharmacologically inferior to amoxicillin, particularly for non- susceptible S. pneumoniae. If used, it should be used in highest dose and shortest interval allowable. See Table 3. f: Amoxicillin is the drug of choice for bacterial CAP due to its favorable pharmacokinetics against S. pneumoniae susceptible and intermediate strains (when dosed 90mg/kg/day divided TID). g: Alternatives to azithromycin for treatment of atypical pathogens include clarithromycin, erythromycin, or if patient is older than 7 years: doxycycline. See text regarding Mycoplasma pneumoniae, Bordetella pertussis, and Chlamydophila pneumoniae reporting off of the standard RPP.

Upload: trinhkhanh

Post on 07-Feb-2018

222 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 1 of 15

UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA

ALGORITHM. Uncomplicated CAP Antibiotic Treatment a

For all patients:· If an atypical pathogen is

suspected (Chlamydophilia

pneumoniae, Bordatella

pertussis, or Mycoplasma

pneumoniae) include

azithromycing

· If CA-MRSA is suspected,

substitute clindamycin or

vancomycin.

· If suspected or confirmed

influenza, consider antiviral

(refer to CDC website for current

recommendations).

Inclusion criteria:Previously healthy pts 90 days

through 21 years of age with signs, symptoms, or

suspected diagnosis of uncomplicated pneumonia

acquired by exposure to organisms in the community.

Exclusion criteria:Pts < 90 days of age (refer to infant fever guidelines)

Pts with complicated pneumonia (refer to complicated

pneumonia guideline)

Immune-compromised host

Medically complicated pts

Pts in need of critical care

Systemic illness concerning for sepsis, hospital

acquired pneumonia,

or illness neccessitating ICU admit

Failed outpatient PO therapy, decreased GI

absorption, or not tolerating PO?

Treat with IV

antibioticsb (follow

algorithm)

Treat with oral

antibioticsb (follow

algorithm)

Yes No

Less than 2 doses of

HiB vaccine?c

Less than 2 doses of

HiB vaccine?c

Treat with IV:

· ampicillin/

sulbactam or

· ceftriaxone or

· cefotaxime

Treat with IV

ampicillin

Treat with oral

amoxicillin/

clavulanated or

certain oral

cephalosporinse

Treat with oral

amoxicillinf

a: Patients with complicated pneumonia (i.e. empyema, large effusion), immunocompromised patients, patients in need of immediate critical care, and those patients with concern for sepsis do NOT fall under this treatment algorithm. Failure of outpatient oral therapy is defined as fever greater than or equal to (≥)38.0°C lasting greater than or equal to (≥) 48 hours 1, and may be due to inadequate choice or dosing of antibiotic, poor compliance, natural history of disease, or resistant organism. b: This is intended for uncomplicated cases only. See Table 3 for dosing recommendations, cost comparisons, and other implications of therapy. c: Assess whether the patient has had 2 or more doses of the H. influenzae type B (HiB) vaccine and consider the risk for invasive H. influenzae B disease based on the vaccine coverage in your community (herd protection). d: Amoxicillin component should be dosed at 90mg/kg/day divided TID if concerned for S. pneumoniae or other isolates with higher MICs (including H. influenzae and S. aureus). If using 90mg/kg/day divided TID dosing, use high dose formulation (Amox/Clav ES Suspension – 600mg/5mL – 42.9mg/5mL or Amox/Clav 875mg-125mg tablets). e: Oral cephalosporin formulations are considered pharmacologically inferior to amoxicillin, particularly for non-susceptible S. pneumoniae. If used, it should be used in highest dose and shortest interval allowable. See Table 3. f: Amoxicillin is the drug of choice for bacterial CAP due to its favorable pharmacokinetics against S. pneumoniae susceptible and intermediate strains (when dosed 90mg/kg/day divided TID). g: Alternatives to azithromycin for treatment of atypical pathogens include clarithromycin, erythromycin, or if patient is older than 7 years: doxycycline. See text regarding Mycoplasma pneumoniae, Bordetella pertussis, and Chlamydophila pneumoniae reporting off of the standard RPP.

Page 2: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 2 of 15

TABLE OF CONTENTS Algorithm

Target Population

Background | Definitions

Initial Evaluation and Monitoring

Table 1. World Health Organization Age-Specific Criteria for Tachypnea

Table 2. Recommended Nomenclature of Adventitious Breath Sounds

Laboratory Studies | Imaging

Clinical Management

Therapeutics

Table 3. CAP Antimicrobials – Dosing, Cost, and Implications of Therapy

Parent | Caregiver Education

Admission | Discharge Criteria

Table 4. Maximum oxygen liter flow for discharge

Follow up

References

Clinical Improvement Team

TARGET POPULATION

Inclusion Criteria

Intended for previously healthy patients:2

· Patients 90 days through 21 years of age

· Patients with signs, symptoms, or other findings suggesting a diagnosis of uncomplicated pneumonia acquired by exposure to organisms in the community.

· Note: For patients under 90 days of age, reference appropriate clinical care guideline for:

o Infant Fever: Age less than 28 days

o Infant Fever: Age 28 to 90 days

Exclusion Criteria

· Patients with complicated pneumonia (i.e., empyema, large effusion)

· Immune-compromised host

· Medically complicated child

· Patients in need of immediate critical care

· Systemic illness concerning for sepsis, hospital acquired pneumonia, or illness necessitating ICU admission

Page 3: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 3 of 15

BACKGROUND | DEFINITIONS

Community Acquired Pneumonia: Infection of airways and lung tissue caused by a multitude of organisms, including a viral and bacterial etiology, which has been acquired outside of the hospital 2

Uncomplicated Pneumonia: Pneumonia in the absence of significant effusion, empyema, severe or impending respiratory failure, and/or signs and symptoms of sepsis or shock

Occult pneumonia: the presence of radiographic pneumonia in children who do not show signs of respiratory distress or lower respiratory tract findings on physical examination 3

INITIAL EVALUATION AND MONITORING

Clinical Assessment

History

· General symptoms of pneumonia include fever, cough, tachypnea, increased work of breathing, and chest pain

· Abdominal pain and or vomiting may be a symptom of pneumonia even in the absence of other respiratory symptoms

· Assessment elements should include:

o Immunization history

o TB exposure including exposure to anyone with a chronic cough

o History of foreign body aspiration risk

o Animal exposure

o Travel history

o Other ill contacts including family members or day care/school exposures

Literature review of predictors of Pneumonia/Diagnosis

The best individual examination measures for predicting pneumonia in children less than 5 years are:4

· Nasal flaring (age less than 12 months) 5

· Decreased oxygen saturation 5**

· Tachypnea (see Table 1 for criteria)5,6

· Retractions 6

o Occult pneumonia has been identified in 6.8% of children who underwent chest radiograph for suspicion of pneumonia7.

o In children with fever 39.0°C or greater and WBC 20,000/mm3 or greater, 9% had evidence of occult pneumonia.7

o Best negative predictive indicator is absence of tachypnea:8 negative predictive value (NPV) 88%

· The best combined group of predictors for radiographic pneumonia are:5

· Fever

· Tachypnea

· Hypoxemia

**This citation is based on patients at elevation lower than Denver, CO. Decreased oxygen saturation at this elevation is typically less than 90% on room air.

Page 4: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 4 of 15

Table 1. World Health Organization Age-Specific Criteria for Tachypnea 8

Examination

· Physical findings commonly present with pneumonia

o Crackles (see Table 2)

o Decreased breath sound intensity

o Bronchial breath sounds—abnormally loud breath sounds audible throughout the respiratory cycle, resembling sounds normally heard only over large airways

o Absence of these findings doesn’t exclude pneumonia

o Wheezing is usually seen with airway inflammation and less commonly seen with pneumonia but may be present with pneumonia

· Physical findings commonly present with pneumonia that may be easier to elicit in older children

o Egophony

o Whispered pectoriloquy

o Increased fremitus

o Bronchophony

Table 2. Recommended Nomenclature of Adventitious Breath Sounds9

Accepted Nomenclature

Acoustic Characteristic

Associated Pathology Typical Phase of respiration

Other commonly associated terminology

Course Crackle Discontinuous “popping” sound

Larger airways popping open associated with edema or inflammation (suggestive of pneumonia)

Inspiration Course rale*

Fine Crackle Higher pitched discontinuous “popping” sound

Smaller airways popping open associated with edema or inflammation (suggestive of pneumonia)

Inspiration Fine rale* Crepitation

Wheeze Continuous high pitched “whistling” sound

Small airway constriction (suggestive of asthma, bronchiolitis, or viral pneumonitis)

Expiration

Rhonchus Continuous low pitched “snoring” sound

More central airway sound often associated with secretions

Inspiration and/or expiration

“coarse breath sound”

*discouraging use of the term “rale” per Pulmonary terms and symbols. A report of the ACCP-STS Joint Committee on Pulmonary Nomenclature10

Age Approximate normal respiratory rates

(breaths/min)

Tachypnea threshold (breaths/min)

2 to 12 months 25 to 40 50

1 to 5 years 20 to 30 40 5 years or over 15 to 25 30

Page 5: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 5 of 15

Monitoring

· Check pulse oximetry 2 with vital signs or with a change in clinical condition.

· Continuous cardiac/pulse oximetry monitoring is only recommended for unstable patients and/or for patients under 3 months of age.

· Patients under 3 months of age; patients who are unstable; and patients who have a history of apnea should have their oxygen titrated to keep SaO2 at or above 90% while on continuous monitoring.

LABORATORY STUDIES | IMAGING

Diagnostic Tests and Studies:

Diagnostic tests are only indicated if they will change outcome.

Radiologic Studies

· Traditionally, diagnosis of pneumonia relies on positive radiographic findings11-13. However, in patients well enough to be treated as outpatients, particularly where radiology services are not readily available, a clinical diagnosis may be made without performing a chest x-ray (CXR).

· CXR should be performed in hospitalized patients with suspected pneumonia. 2-view CXR2 is encouraged to:

o Establish diagnosis of pneumonia

o Evaluate for foreign body

o Promote judicious use of antibiotics

o Direct appropriate therapy

· Repeat CXR is only indicated for clinical deterioration or lack of clinical improvement2.

· If child has recurrent pneumonia (defined as 3 times in lifetime or 2 times within 6 months), consider repeat CXR in 4 to 6 weeks2 after clinical resolution to confirm radiographic resolution.

Laboratory studies

· CBC

o CBC and differential should not be obtained unless adjunctive information is necessary to help decide whether to use antibiotics14-16

· Note: CBC has a limited role, and is often not useful, in differentiating between viral and bacterial

pneumonia 17,18

o In young children (less than age 5), presenting with fever without source (temperature 39°C or greater), significant leukocytosis (WBC 20,000/mm3 or greater) may be predictive of radiographic pneumonia (9% have radiographic evidence of pneumonia)7

· CRP/ESR

o C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and other measures of acute phase reactants should not be performed, as these tests are not specific enough to be useful14,15,17,19,20

Clinical Titration of Oxygen for Stable Infants over 3 Months of Age

1. If respiratory rate is less than 50 bpm, minimal retractions, and child is active and feeding well: wean oxygen flow in increments of 0.125 to 0.5 Lpm. Assess for titration of oxygen at least every 4 hours.

2. If respiratory rate is rapid for age, infant has significant retractions or nasal flaring, or infant is feeding poorly: increase oxygen incrementally. Consider continuous pulse oximetry if oxygen flow is greater than 1 Lpm for infants 3 to 6 months of age or greater than 2 Lpm for children older than 6 months.

Page 6: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 6 of 15

o ESR and procalcitonin have a limited role in differentiating viral from bacterial pneumonia, and the sensitivity of CRP is too poor to be clinically useful.2,17,18

Note: CBC/ESR/CRP may be used to help monitor response in patients who aren’t typically improving with initial therapy or those who present with systemic illness concerning for sepsis (this population is excluded in this CCG).

· Viral Studies

o Viral testing is indicated if results would change management

· Testing for atypical bacteria (see additional considerations for atypical bacteria below)

· Sputum

o Consider Gram stain and culture on high quality specimens when managing children capable of producing an adequate sample (typically school age)2,21.

· Note: A high quality sputum is usually defined by the presence of less than 10 squamous epithelial cells

and greater than 25 WBCs per low power field21

· Tuberculin Skin Testing (TST)

o TST or IGRA should be conducted in children with a history of exposure to tuberculosis, chronic cough, personal or family travel in areas where tuberculosis is prevalent, per RedBook recommendations.22

o TB isolation precautions and notification of epidemiology is required if TB is strongly suspected or confirmed.

· Blood Cultures

o Blood cultures should not be routinely obtained in outpatients2,23,24

· Note: When pneumonia is diagnosed in an outpatient setting, the likelihood of a positive blood culture is less than 2.7%24

o Blood cultures are not recommended for hospitalized children with presumed moderate to severe bacterial pneumonia (bacteremia risk 0-6%)25,26, but should be strongly considered for children with complicated pneumonia.2

o If child is well appearing and reliable follow-up can be assured, discharge to home should not be delayed for final results of blood culture.

· Urinary Antigen Detection Tests

o Urinary antigen detection tests are not recommended for the diagnosis of pneumococcal pneumonia in children2

· Other

o When historical, physical, radiologic, or laboratory findings are inconsistent, additional studies should be considered to evaluate for alternative or coincident conditions, such as foreign body aspiration or immunodeficiency.

o Consider pertussis PCR for patients when predominant clinical component is cough, particularly if paroxysmal, or prolonged, or diagnosis supported epidemiologically

CLINICAL MANAGEMENT

Prevention

· Hand hygiene

· Isolation procedures

· Influenza and pneumococcal vaccines

Page 7: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 7 of 15

THERAPEUTICS (REFER TO ALGORITHM AND TABLE 3)

· In children less than 5 years of age, etiology is much more likely to be viral and routine use of antibiotics is not recommended (viral causes include Influenza A and B, Respiratory syncytial virus, Parainfluenza viruses, Human metapneumovirus, Adenovirus, and Rhinovirus)

· Common bacterial causes of pneumonia in childhood include the following:

o Streptococcus pneumoniae

o Staphyloccocus aureus (including MRSA)

o Haemophilus influenza (if under-immunized)

o Group A streptococcus

o Atypical pathogens (Bordetella pertussis, Mycoplasma pneumoniae – school age children, Chlamydophila pneumoniae – school age children)

· Route of treatment:

o According to PIDSA Guidelines2, “Children with suspected bacterial CAP that is serious enough to warrant hospitalization should routinely be treated with parenteral antibiotics to provide reliable blood and tissue concentrations.” Therefore, IV antibiotics for initial therapy should be considered in patients with uncomplicated CAP admitted to the hospital with vomiting or suspected decreased GI absorption.

o For patients with mild illness, initial therapy with oral antibiotics may be appropriate.

o Failure of outpatient oral therapy is defined as fever greater than or equal to (≥)38.0°C lasting greater than or equal to (≥) 48 hours 1, and may be due to inadequate choice or dosing of antibiotic, poor compliance, natural history of disease, or resistant organism. It is still reasonable to treat intravenously with narrow choice (ampicillin, good coverage for most Streptococcus pneumoniae and 70% of Haemophilus influenzae), as pharmacokinetics far superior to oral amoxicillin or cephalosporins. Other choices should be used if gram

negatives suspected, or Staphylococcus aureus suspected (see Table 3) 27-29.

· Duration of treatment:

o Duration of antimicrobial therapy is suggested to be 5-7 days for non-severe CAP 30,31.

o If child fails to improve within 48 to 72 hours of initiation of treatment, consider alternate diagnosis or therapy 2.

· Modification of treatment:

o Should specific pathogen identification become available, tailor antibiotic therapy based on microbiology results

Additional considerations for the treatment of Mycoplasma pneumoniae (and other atypical pathogens):

· Azithromycin cannot be used to treat Streptococcus pneumoniae pneumonia, so should only be considered “if atypical suspected” AND Streptococcus pneumoniae is not suspected. No clear definition of atypical pneumonia exists, however it is often interpreted as pneumonia in school-aged children with more diffuse abnormal breath sounds, and/or chest x-ray, or those who have failed initial treatment for Streptococcus pneumoniae. On occasion, mycoplasma can cause a lobar pneumonia, but this is not a usual finding.

· The literature is limited and not clear that there is benefit to treating Mycoplasma pneumoniae lower tract infection.

o A multi-center retrospective database cohort study of children hospitalized with Mycoplasma pneumoniae reported empiric use of macrolide therapy was associated with a shorter hospital length of stay (median 3 days in treated patients compared to 4 days in un-treated patients) 32.

o Systematic reviews conclude that the available literature does not support or refute treatment of lower respiratory tract infection due to Mycoplasma pneumonia 33-35.

Page 8: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 8 of 15

· Testing and treatment for Mycoplasma pneumoniae is not routinely recommended. If testing is obtained (e.g. CHCO respiratory pathogen panel), children with a negative test should not be treated. Children with a positive test do not have to be treated. For example, a provider may elect not to treat because data for benefit is unclear (particularly late in course), risks of antimicrobials may outweigh benefit, or Mycoplasma PCR may be positive for extended periods and may not reflect disease.

· The CHCO rapid pathogen panel (RPP) tests for both Mycoplasma pneumoniae and Chlamydophila pneumoniae; routine testing is not recommended, but testing is indicated if results will change management (i.e. will lead to: targeted treatment of mycoplasma, discontinued treatment for mycoplasma, discontinued treatment for traditional CAP organisms, or no treatment at all).

Pneumonia in the setting of influenza:

· Pneumonia is a common complication in children hospitalized with influenza.

o In one study, 27% of children hospitalized with laboratory confirmed influenza had radiologically confirmed pneumonia. Children aged 6 months to 4 years and those with underlying asthma were more likely to have pneumonia. Staphylococcus aureus was the most commonly identified bacterial co-infection in children with influenza-associated pneumonia36.

· Children hospitalized with influenza co-infected with S. aureus have higher rates of severe outcomes (ICU

admission, death)37.

· It may be difficult to differentiate primary viral (influenza) pneumonia from secondary bacterial pneumonia. Indicators of bacterial superinfection may include: secondary fever after a period of defervescence, lobar

· consolidation, increased WBC, and later onset (4 to 7 days) of respiratory compromise after initial symptoms38.

· Empiric coverage for S. aureus infection in children hospitalized with influenza-associated pneumonia should be

considered.

Other Therapies

· Therapies directed towards airway clearance (CPT, VEST, cough assist) should not be used for patients with uncomplicated pneumonia 39,40; there are some studies that suggest it can be harmful to some patient 41.

o Chest physiotherapy does not decrease length of stay in children hospitalized with pneumonia 42.

o Gentle activity should be encouraged as the best way to mobilize secretions. In infants repositioning is considered a form of gentle activity 43.

o Bronchodilators should not be routinely used unless there is known component of asthma. Wheezing that is typically heard in a patient with pneumonia is most likely related to airway inflammation 43.

o There is no evidence-based literature to support the use of intermittent positive pressure therapy (EzPAP) in pediatrics with pneumonia.

Page 9: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 9 of 15

Table 3: CAP Antimicrobials – Dosing, Cost, and Implications of Therapy

Antibiotic Recommended Dose Costa Implications of Therapy

Amoxicillin (PO)

PREFERRED:

90mg/kg/day divided TID

(max: 3,000mg/day)

OTHER:

90mg/kg/day divided BIDb

$45

(liquid more

expensive)

· 90mg/kg/day divided TID is the best choice for susceptible and intermediate S. pneumoniae in

order to achieve adequate time above the MIC.

o Other regimens acceptable for susceptible, but not intermediate, S. pneumoniae.

o Only 75% of S. pneumoniae at Children’s Colorado are fully susceptible

· 90mg/kg/day divided TID is also encouraged for other bacterial organisms implicated in CAP

with higher MICs, including H. influenzae and S. aureus.

Amoxicillin/

Clavulanate

(PO)

**Take note of appropriate

formulation choice**

PREFERRED:

90mg/kg/day divided TID

(max: 3,000mg/day if using

suspension and 2,625mg/day

if using tablet)

OTHER:

90mg/kg/day divided BIDb

$88 generic

(liquid more

expensive)

· See comments for amoxicillin

· Amoxicillin/clavulanate adds some gram negative, MSSA, and anaerobic coverage and should be

reserved for patients in which expanded coverage is desirable (i.e. under-immunized)

· It is recommended that total daily dose of clavulanate remain below 10mg/kg/day to mitigate

GI side effects

· Ratio of amoxicillin and clavulanate components vary, so not all formulations can be used for

“high” or “low” dosing.

o Formulations for “high” dosing (90mg/kg/day)

▪ Amoxicillin-clavulanate ES suspension 600-42.9mg/5mL

▪ Amoxicillin-clavulanate 875-125mg tablets (be aware of max clavulanate dosing)

o Formulations for “low” dosing (45mg/kg/day)

▪ Amoxicillin-clavulanate suspension 400-57mg/5mL

▪ Amoxicillin-clavulanate 500-125mg tablets

▪ Amoxicillin-clavulanate 200-28.5mg chewable tablets

Ampicillin (IV) 200mg/kg/day divided q6h

(max: 8,000mg/day) --

· Preferred intravenous antibiotic for initial treatment

Ampicillin/

Sulbactam (IV)

200mg/kg/day divided q6h

(max: 8,000mg/day) --

Cefotaxime (IV) 150mg/kg/day divided q8h

(max: 6,000mg/day) --

· Can be used for penicillin-allergic patients

· If a PO transition is warranted, it is recommended that either amoxicillin or amoxicillin-

clavulanate be prescribed given the unfavorable pharmacokinetic profile of oral cephalosporins

in the treatment of CAP.

Cefpodoxime (PO) 10mg/kg/day divided BID

(max: 400mg/day)

$143

(brand)

· Can be used as an alternative for PCN allergic patients; however, cephalosporin formulations are

considered to pharmacologically inferior to amoxicillin, particularly for non-susceptible S.

pneumoniae.

· Has relatively poor oral absorption and higher protein binding compared to amoxicillin, making

it more difficult to treat non-susceptible S. pneumoniae.

· A max dose of 800mg/day can be used in patients with complicated community-acquired

pneumonia.

Cefprozil (PO)c 30mg/kg/day divided BID

(max: 1.000mg/day) $174

· Can be used as an alternative for PCN allergic patients; however, cephalosporin formulations are

considered to pharmacologically inferior to amoxicillin, particularly for non-susceptible S.

pneumoniae.

· Has relatively poor oral absorption and higher protein binding compared to amoxicillin

Ceftriaxone (IV) 50mg/kg/day q24h

(max: 2,000mg/day) --

· Can be used for penicillin-allergic patients

· If a PO transition is warranted, it is recommended that either amoxicillin or amoxicillin-

clavulanate be prescribed given the unfavorable pharmacokinetic profile of oral cephalosporins

in the treatment of CAP.

Cefuroxime axetil

(PO)c

30mg/kg/day divided BID

(max: 1,000mg/day) $440 (brand)

· Can be used as an alternative for PCN allergic patients; however, cephalosporin formulations are

considered to pharmacologically inferior to amoxicillin, particularly for non-susceptible S.

pneumoniae.

· Has relatively poor oral absorption and higher protein binding compared to amoxicillin

Azithromycin

(IV or PO)

10mg/kg/day 1st day, followed

by 5mg/kg/day (max:

500mg/day)

$43

· ONLY indicated for coverage of atypical pneumonias as 40% of CHCO S. pneumoniae isolates are

predicted to be resistant.

· If an RPP is ordered and Mycoplasma pneumoniae is not detected, it is strongly encouraged to

discontinue azithromycin therapy.

Clindamycin

(IV or PO)

30-40mg/kg/day divided TID

(max PO: 1,800mg/day, max IV:

2,700mg/day)

$360 · 27% of our S. pneumoniae is resistant

· 14% of our S. aureus is resistant

a: Cost based on 20kg child x 10 days, purchased from Walgreen’s pharmacy suspension formulation in Colorado for cash-paying customers during third quarter of 2014.; b: Twice daily dosing may be considered for outpatient use if compliance is a concern.; c: Non-formulary agent at CHCO. May be used if prescribing to an outpatient and insurance coverage warrants.

Page 10: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 10 of 15

PARENT | CAREGIVER EDUCATION

Pneumococcal Disease (English)

Pneumococcal Disease (Spanish)

Home Oxygen Therapy (English version)

Home Oxygen Therapy (Spanish version)

ADMISSION | DISCHARGE CRITERIA

Admission

· Critical care 2

o Respiratory failure or impending respiratory failure [hypercapnia, acidosis, supplemental O2 need greater than 50% FiO2, severe dehydration, altered mental status, ventilation (invasive or noninvasive) with need for increased support, underlying neuromuscular issues, or compromised ability to handle secretions or maintain airway]

o Sustained tachycardia, hypotension, or need for pharmacologic support of blood pressure or perfusion

· Inpatient setting; one or more of the following

o Cannot take antibiotics orally

o Dehydration requiring IV fluids

o Hypoxemia

o Concern or risk for progressive or complicated pneumonia

· Discharge home

o Oxygen requirements: See Table 4

Table 4. Maximum oxygen liter flow for discharge

o Stable and improving hypoxemia and improving clinical status, patients may be discharged home on O2 after

24 hours or more of observation and treatment. These clinical care guidelines are designed to assist clinicians and patients make decisions about appropriate care of the patient with uncomplicated community acquired pneumonia and are not meant as a substitute for sound clinical judgment.

o Reliable follow up and social situation

o Clinical status:

· Respiratory rate approaching normal as expected for age

· Normal work of breathing

· Able to maintain hydration orally

· Baseline mental status

Age of Patient: Maximum liter flow for discharge:

Less than 24 months and stable ½ liter per minute or less

Older than 24 months and stable 1 liter per minute or less

Page 11: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 11 of 15

· Medications

o Able to take medications orally

o Able to obtain prescription to complete course

FOLLOW UP

· Establish PCP follow up within 2 to 3 days

Page 12: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 12 of 15

REFERENCES

1. Lahti E, Peltola V, Virkki R, Ruuskanen O. Influenza pneumonia. The Pediatric infectious disease journal 2006;25:160-4.

2. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53:e25-76.

3. Shah S, Mathews B, Neuman MI, Bachur R. Detection of occult pneumonia in a pediatric emergency department. Pediatric emergency care 2010;26:615-21.

4. Ebell M. Clinical diagnosis of pneumonia in children. Am Fam Physician 2010;82:192-3. 5. Mahabee-Gittens EM, Grupp-Phelan J, Brody AS, et al. Identifying children with pneumonia in the emergency

department. Clinical pediatrics 2005;44:427-35. 6. Harari M, Shann F, Spooner V, Meisner S, Carney M, de Campo J. Clinical signs of pneumonia in children. Lancet

(London, England) 1991;338:928-30. 7. Rutman MS, Bachur R, Harper MB. Radiographic pneumonia in young, highly febrile children with leukocytosis

before and after universal conjugate pneumococcal vaccination. Pediatric emergency care 2009;25:1-7. 8. Shah S, Bachur R, Kim D, Neuman MI. Lack of predictive value of tachypnea in the diagnosis of pneumonia in

children. The Pediatric infectious disease journal 2010;29:406-9. 9. Murphy RL. In defense of the stethoscope. Respiratory care 2008;53:355-69. 10. n.a. Pulmonary terms and symbols. A report of the ACCP-STS Joint Committee on Pulmonary Nomenclature.

Chest 1975;67:583-93. 11. Redd SC, Patrick E, Vreuls R, Metsing M, Moteetee M. Comparison of the clinical and radiographic diagnosis of

paediatric pneumonia. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88:307-10. 12. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society

consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44 Suppl 2:S27-72.

13. McIntosh K. Community-acquired pneumonia in children. The New England journal of medicine 2002;346:429-37. 14. Korppi M. Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia:

what is the most accurate combination? Pediatrics international : official journal of the Japan Pediatric Society 2004;46:545-50.

15. Toikka P, Irjala K, Juven T, et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. The Pediatric infectious disease journal 2000;19:598-602.

16. Bachur R, Perry H, Harper MB. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Annals of emergency medicine 1999;33:166-73.

17. Virkki R, Juven T, Rikalainen H, Svedstrom E, Mertsola J, Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax 2002;57:438-41.

18. Don M, Valent F, Korppi M, Canciani M. Differentiation of bacterial and viral community-acquired pneumonia in children. Pediatrics international : official journal of the Japan Pediatric Society 2009;51:91-6.

19. Heiskanen-Kosma T, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. Scandinavian journal of infectious diseases 2000;32:399-402.

20. Ruuskanen O, Mertsola J. Childhood community-acquired pneumonia. Seminars in respiratory infections 1999;14:163-72.

21. Skerrett SJ. Diagnostic testing for community-acquired pneumonia. Clinics in chest medicine 1999;20:531-48. 22. Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-

acquired pneumonia. Respiratory medicine 2004;98:488-94. 23. Claesson BA, Trollfors B, Brolin I, et al. Etiology of community-acquired pneumonia in children based on antibody

responses to bacterial and viral antigens. The Pediatric infectious disease journal 1989;8:856-62. 24. Hickey RW, Bowman MJ, Smith GA. Utility of blood cultures in pediatric patients found to have pneumonia in the

emergency department. Annals of emergency medicine 1996;27:721-5. 25. Murtagh Kurowski E, Shah SS, Thomson J, et al. Improvement methodology increases guideline recommended

blood cultures in children with pneumonia. Pediatrics 2015;135:e1052-9. 26. Heine D, Cochran C, Moore M, Titus MO, Andrews AL. The prevalence of bacteremia in pediatric patients with

community-acquired pneumonia: guidelines to reduce the frequency of obtaining blood cultures. Hospital pediatrics 2013;3:92-6.

27. Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics 2014;133:e23-9.

Page 13: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 13 of 15

28. Thomas NM, Brook I. Otitis media: an update on current pharmacotherapy and future perspectives. Expert opinion on pharmacotherapy 2014;15:1069-83.

29. Williams DJ, Edwards KM, Self WH, et al. Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines. Pediatrics 2015;136:44-52.

30. Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. The Pediatric infectious disease journal 2014;33:136-42.

31. Esposito S, Cohen R, Domingo JD, et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? The Pediatric infectious disease journal 2012;31:e78-85.

32. Shah SS, Test M, Sheffler-Collins S, Weiss AK, Hall M. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia. Journal of hospital medicine 2012;7:311-7.

33. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics 2014;133:1081-90.

34. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. The Cochrane database of systematic reviews 2008:Cd004418.

35. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. The Cochrane database of systematic reviews 2015;1:Cd004875.

36. Dawood FS, Fiore A, Kamimoto L, et al. Influenza-associated pneumonia in children hospitalized with laboratory-confirmed influenza, 2003-2008. The Pediatric infectious disease journal 2010;29:585-90.

37. Reed C, Kallen AJ, Patton M, et al. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. The Pediatric infectious disease journal 2009;28:572-6.

38. Wright PF, Kirkland KB, Modlin JF. When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia. The New England journal of medicine 2009;361:e112.

39. Hardy KA. A review of airway clearance: new techniques indications and recommendations. Respiratory Care 1994;39:440.

40. De Boeck K, Vermeulen F, Vreys M, Moens M, Proesmans M. Airway clearance techniques to treat acute respiratory disorders in previously healthy children: where is the evidence? European journal of pediatrics 2008;167:607-12.

41. Selsby DS. Chest physiotherapy. BMJ (Clinical research ed) 1989;298:541-2. 42. Paludo C, Zhang L, Lincho CS, Lemos DV, Real GG, Bergamin JA. Chest physical therapy for children

hospitalised with acute pneumonia: a randomised controlled trial. Thorax 2008;63:791-4. 43. Pediatric pneumonia treatment & management. n.d. (Accessed March 17, 2010, at

http://emedicine.medscape.com/article/967822-treatment#aw2aab6b6b4.)

Page 14: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 14 of 15

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an “as is” basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.

CLINICAL IMPROVEMENT TEAM MEMBERS

Jenny Reese, MD | Hospital Medicine

Leonard ‘Barry’ Seltz, MD | Hospital Medicine

Leigh Anne Bakel, MD | Hospital Medicine

Sarah Parker, MD | Infectious Disease

Oren Kupfer, MD | Pulmonary Medicine

Amanda Hurst, PharmD | Clinical Pharmacist

Jason Child, PharmD | Clinical Pharmacist

Sarah Nickels, PhD | Clinical Effectiveness

APPROVED BY

Clinical Care Guideline and Measures Review Committee – October 11, 2016 Antimicrobial Stewardship Committee – not applicable Pharmacy & Therapeutics Committee – October 6, 2016

MANUAL/DEPARTMENT Clinical Care Guidelines/Quality

ORIGINATION DATE November 5, 2015

LAST DATE OF REVIEW OR REVISION October 11, 2016

APPROVED BY

Lalit Bajaj, MD, MPH Medical Director, Clinical Effectiveness

REVIEW/REVISION SCHEDULE

Scheduled for full review on October 11, 2019

Page 15: Community Acquired Pneumonia (CAP), Uncomplicated · PDF fileCLINICAL PATHWAY Page 1 of 15 UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA ALGORITHM. Uncomplicated CAP Antibiotic Treatment

CLINICAL PATHWAY

Page 15 of 15